Margriet V D Z Park

List of Publications by Year
in descending order

26	2,677	394421 19	580821 25
papers	citations	h-index	g-index

26	26	26	5238
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials, 2011, 32, 9810-9817.	11.4	864
2	Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Particle and Fibre Toxicology, 2014, 11, 18.	6.2	254
3	Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials, 2013, 34, 8333-8343.	11.4	239
4	Particle size dependent deposition and pulmonary inflammation after short-term inhalation of silver nanoparticles. Particle and Fibre Toxicology, 2014, 11, 49.	6.2	168
5	A perspective on the developmental toxicity of inhaled nanoparticles. Reproductive Toxicology, 2015, 56, 118-140.	2.9	143
6	In vitro developmental toxicity test detects inhibition of stem cell differentiation by silica nanoparticles. Toxicology and Applied Pharmacology, 2009, 240, 108-116.	2.8	134
7	Progress and future of in vitro models to study translocation of nanoparticles. Archives of Toxicology, 2015, 89, 1469-1495.	4.2	117
8	Considerations for Safe Innovation: The Case of Graphene. ACS Nano, 2017, 11, 9574-9593.	14.6	94
9	The status of in vitro toxicity studies in the risk assessment of nanomaterials. Nanomedicine, 2009, 4, 669-685.	3.3	93
10	Genotoxicity evaluation of amorphous silica nanoparticles of different sizes using the micronucleus and the plasmidlacZgene mutation assay. Nanotoxicology, 2011, 5, 168-181.	3.0	78
11	Identification of the appropriate dose metric for pulmonary inflammation of silver nanoparticles in an inhalation toxicity study. Nanotoxicology, 2016, 10, 1-11.	3.0	62
12	Horizon scan of nanomedicinal products. Nanomedicine, 2015, 10, 1599-1608.	3.3	62
13	A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. International Journal of Nanomedicine, 2016, 11, 2935.	6.7	53
14	Quality evaluation of human and environmental toxicity studies performed with nanomaterials â€“ the GUIDEnano approach. Environmental Science: Nano, 2018, 5, 381-397.	4.3	48
15	Nanomedicinal products: a survey on specific toxicity and side effects. International Journal of Nanomedicine, 2017, Volume 12, 6107-6129.	6.7	46
16	A practical approach to determine dose metrics for nanomaterials. Environmental Toxicology and Chemistry, 2015, 34, 1015-1022.	4.3	36
17	Assessment of oxidative damage induced by iron oxide nanoparticles on different nervous system cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 845, 402989.	1.7	34
18	Bridging communities in the field of nanomedicine. Regulatory Toxicology and Pharmacology, 2019, 106, 187-196.	2.7	32

#	Article	IF	Citations
19	Simplein vitromodels can predict pulmonary toxicity of silver nanoparticles. Nanotoxicology, 2016, 10, 770-779.	3.0	31
20	Development of a systematic method to assess similarity between nanomaterials for human hazard evaluation purposes â€“ lessons learnt. Nanotoxicology, 2018, 12, 652-676.	3.0	21
21	In vitro evaluation of cytotoxic and inflammatory properties of silica nanoparticles of different sizes in murine RAW 264.7 macrophages. Journal of Nanoparticle Research, 2011, 13, 6775-6787.	1.9	19
22	Sensitive method for endotoxin determination in nanomedicinal product samples. Nanomedicine, 2019, 14, 1231-1246.	3.3	13
23	Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin Determination. Current Bionanotechnology, 2017, 2, 95-102.	0.6	12
24	Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1633.	6.1	11
25	Interactions with the Human Body. , 2012, , 3-24.		9
26	Systematic selection of a dose metric for metal-based nanoparticles. NanoImpact, 2019, 13, 70-75.	4.5	4